



Impacts of Genome-Wide Analyses on Our Understanding of Human Herpesvirus Diversity and Evolution

Daniel W. Renner,^a  Moriah L. Szpara^a

^aDepartment of Biochemistry and Molecular Biology, Center for Infectious Disease Dynamics, and the Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, Pennsylvania, USA

ABSTRACT Until fairly recently, genome-wide evolutionary dynamics and within-host diversity were more commonly examined in the context of small viruses than in the context of large double-stranded DNA viruses such as herpesviruses. The high mutation rates and more compact genomes of RNA viruses have inspired the investigation of population dynamics for these species, and recent data now suggest that herpesviruses might also be considered candidates for population modeling. High-throughput sequencing (HTS) and bioinformatics have expanded our understanding of herpesviruses through genome-wide comparisons of sequence diversity, recombination, allele frequency, and selective pressures. Here we discuss recent data on the mechanisms that generate herpesvirus genomic diversity and underlie the evolution of these virus families. We focus on human herpesviruses, with key insights drawn from veterinary herpesviruses and other large DNA virus families. We consider the impacts of cell culture on herpesvirus genomes and how to accurately describe the viral populations under study. The need for a strong foundation of high-quality genomes is also discussed, since it underlies all secondary genomic analyses such as RNA sequencing (RNA-Seq), chromatin immunoprecipitation, and ribosome profiling. Areas where we foresee future progress, such as the linking of viral genetic differences to phenotypic or clinical outcomes, are highlighted as well.

KEYWORDS herpesvirus, bioinformatics, diversity, evolution, genetic recombination, genomics, minority variant, polymorphism, viral pathogenesis

Herpesviruses infect and affect every human on the planet, with a universally penetrant global public health impact (1–4). Most adult humans carry one or more members of the nine herpesvirus families that infect our species. These include the alpha-subfamily members herpes simplex virus 1 and 2 (HSV-1/2 or human herpesvirus 1 and 2 [HHV-1/2]) and varicella-zoster virus (VZV or HHV-3); the beta-subfamily of human cytomegalovirus (HCMV or HHV-5) and human herpesviruses 6A, 6B, and 7 (HHV-6A/6B/7); and the gamma-subfamily of Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) (5). Advances in our understanding of the molecular biology and evolution of these herpesviruses have been informed and advanced by work on other large DNA viruses such as poxviruses of humans and animals; multiple families of bacteriophage, baculoviruses, and other insect viruses; and amoebal giant viruses such as mimivirus (6).

Here we review recent studies that have used high-throughput sequencing (HTS) and genome-wide analyses to explore the diversity and evolution of herpesviruses. In the first half of this review, we examine data suggesting that the diversity and evolution of herpesviruses are impacted by mechanisms extending beyond the usual consideration of polymerase fidelity. These include the influence of minority alleles and standing variation in the virus population, recombination between viral genomes, horizontal gene transfer, and nontemplated mechanisms such as ribosome frameshifting and RNA

Accepted manuscript posted online 18 October 2017

Citation Renner DW, Szpara ML. 2018. Impacts of genome-wide analyses on our understanding of human herpesvirus diversity and evolution. *J Virol* 92:e00908-17. <https://doi.org/10.1128/JVI.00908-17>.

Editor Britt A. Glaunsinger, University of California, Berkeley

Copyright © 2017 Renner and Szpara. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Moriah L. Szpara, moriah@psu.edu.




FIG 1 Opportunities for change in a given viral population arise both *in vivo* and *in vitro*. (A) The viral population in an infected individual (represented by red or red-shaded virion) may change over time due to immune selection or the accumulation of genetic drift. Bottlenecks at transmission to a new host or during introduction to tissue culture may allow a new genotype to become prevalent, akin to a genetic shift. (B) A viral stock grown in culture is also a viral population, which may undergo changes during introduction to an animal model or through plaque purification. See Fig. 2 for an expanded view of the genomes contained in the viral population.

editing (Fig. 1 and 2). We also consider how these mechanisms of variation impact our ability to manipulate herpesviruses in culture. In the second half of this review, we summarize the tremendous gains in identifying the genetic diversity found among the members of each species of human herpesvirus. We explore how to accurately describe the viral populations that researchers handle experimentally. The necessity for a strong foundation of high-quality genomes—and the bioinformatics tools that enable their production—are also discussed. Many new insights have been enabled by the application of HTS and bioinformatics to herpesvirus genomes, and we end with the challenges that lie ahead.

(IN)STABILITY OF LARGE DNA VIRUSES

The perception of most virologists is that RNA viruses are inherently variable and that DNA viruses are inherently stable (7, 8). At the molecular level, this view stems from the lack of error correction by most RNA-dependent RNA polymerases. In contrast to RNA viruses, most DNA viruses display high polymerase fidelity and error correction. For herpesviruses such as HSV-1, early studies of mutation rates focused on single genes and detected mutation rates in the range of $\sim 1 \times 10^{-7}$ or $\sim 1 \times 10^{-8}$ mutations per base per infectious cycle (9, 10). These rates are often quoted in comparisons of RNA viruses to DNA viruses (7, 8, 11) and are matched by restriction-fragment length polymorphism (RFLP) analyses comparing herpesviruses from disparate geographic locations (12). However, these data fail to explain the surprising ease with which herpesvirus variants can be selected or revealed (Fig. 1). For instance, drug-resistant mutations can be selected from drug-sensitive HSV-1 and HSV-2 populations at a rate of 1 in 10^4 or 1 in 10^3 PFU (13). This suggests that the rate of standing variation in the population in herpesviruses may be higher than previously appreciated (14) and/or that the different time scales of experimental settings versus evolutionary comparisons are at odds (15).

There are data to support both the hypothesis of standing variation and that of differing time scales. Using HTS approaches, several studies have described the existence and expansion of standing variation in HCMV populations in nonimmunocompetent hosts, such as congenitally infected infants and immunosuppressed or transplant patients (16–20). In a short-time-scale investigation of Muller's ratchet—the hypothesis that small asexual populations accumulate deleterious mutations—Jaramillo et al. took 10 individual subclones of HSV-1 and subjected each to repeated population bottlenecks through sequential plaque-to-plaque transfers (21). Two clonal

lineages were completely lost during this process, and single-gene analysis of the remaining clones revealed a mutation frequency of 3.6×10^{-4} substitutions per base per plaque transfer. The authors also found reduced mortality after intracerebral inoculation into mice for these serially passaged clones (21). Even in the absence of intentional selective pressure, genome-wide HTS comparisons of HSV-1 and HCMV subclones have revealed nucleotide variations in up to 3% to 4% of the genome (22–25). A higher-than-expected frequency of observed mutations in herpesvirus populations was also found in a recent application of phylodynamic inference to DNA viruses, which estimated the substitution rate of HSV-1 to be $\sim 1 \times 10^{-5}$ or $\sim 1 \times 10^{-4}$ mutations per base per year (15). Many of the studies cited above have focused on HSV-1 as a model herpesvirus, but there may well be subfamily- or species-specific differences in the amount of standing variation in the population, the number of replicative cycles per year, and/or the selection pressures faced during viral transmission in real-world settings. Innovative combinations of genome-wide HTS applications, with models that account for positive selection and standing variation, will be needed to bring these diverse data into synchrony.

RECOMBINATION AS A DRIVING FORCE IN DNA VIRUS EVOLUTION

Mutation and evolution in herpesviruses result not only from base substitutions but also from recombination between strains and, to a lesser extent, between species. Recombination in herpesviruses can provide a driving force for evolutionary shifts, akin to that associated with reassortment in segmented RNA viruses (26). HTS studies of laboratory-generated recombinants of HSV-1 have revealed a bias toward breakpoints being detected in repetitive tracts, intergenic regions, and areas of higher G+C content (27). However, most studies of recombination in human herpesviruses have focused on naturally circulating variants and have inferred historical sites of recombination and phylogenetic relationships from the comparison of disparate strains. For example, increased genomic surveillance of VZV has expanded the number of known phylogenetic clades for this species in recent years; this has provided evidence for ancient, interclade recombination as well as for modern recombination between individual strains (28–32). For the beta-herpesvirus HCMV, multiple groups have confirmed the finding of rampant genome-wide recombination among different HCMV strains (19, 33, 34). Lassalle et al. focused most deeply on this aspect of HCMV evolution and found that particular sections or islands of the HCMV genome appeared to cosegregate, whereas widespread recombination between strains was detected everywhere else in the genome (34). The authors postulated that genes in these islands are codependent, thus enabling higher fitness and a selective advantage for genomes that lack recombination events inside these regions.

In the case of the alpha-herpesvirus HSV-1, there is evidence of rampant recombination between different isolates or strains, but not yet sufficient data to discern whether the recombination events are ancient or extant (35, 36). Evidence for ancient recombination between HSV-1 and the distantly related species HSV-2 has been found by two separate groups (37, 38), who recently described several loci in the HSV-2 genome that contained HSV-1-like DNA. This inference is based on the high similarity of these regions to extant HSV-1 genomes and on their divergence from a unique and apparently historical HSV-2 genotype that has thus far been found only in Africa (39, 40). Additional evidence of modern recombination in natural settings stems from the veterinary herpesvirus literature (41). In 2012, Lee and colleagues demonstrated that a virulent avian herpesvirus that had created an outbreak in Australian poultry was in fact a spontaneous recombinant resulting from two live-attenuated vaccines that were both in use (42). This example is bolstered by multiple others among the veterinary herpesviruses which have been reviewed recently elsewhere (41). The next challenge for understanding herpesvirus recombination events is to address where and how often they occur *in vivo*, since recombination requires the co-occurrence of two distinct viral genomes in a single cell of the same host—an event which may be rare and difficult to detect in clinical or field settings.

LOSING OR GAINING GENE FUNCTIONS IN CULTURE

Our ability to conduct experimental studies of herpesviruses, and to develop therapeutics and vaccines, depends vitally on cell culture techniques. However, cell culture can induce unintentional selective pressure on viral populations, as has been recognized most notably in the case of HCMV. Prior studies revealed that laboratory strains of HCMV such as AD169 and Towne had not only accumulated minor changes associated with genetic drift but also lost multiple genes during their adaptation to cell culture (22, 24, 43). The regions lost *in vitro* had functions associated with cell tropism and immune evasion *in vivo*. Although no similar link between frequent deletions and loss of *in vivo*-specific functions has yet been discovered for other herpesviruses, a tendency for loss of specific genomic regions has been observed. Frequent deletion of the UL55-UL56 region has been observed in cultured HSV-1 strains, although the phenotypic impact of this loss is unknown (36). The loss of genomic regions has also been demonstrated in other large DNA viruses such as mimivirus, which undergoes gene loss from its termini during repeated passage in amoebal culture (44). There is a pressing need to document the nature of any changes that occur during herpesvirus introduction to culture and subsequent passages thereafter, so that the accumulation of genetic drift and/or the selective pressures of cell culture can be better understood.

Although viral propagation in cell culture can induce the loss of gene functions required for *in vivo* growth, it can also facilitate experimental insights by revealing transient genome intermediates in the process of viral adaptation. This was demonstrated in a recent study using HTS and comparative genomics in the poxvirus vaccinia virus (VACV), which relies on two viral antagonists to combat the host antiviral protein kinase R (PKR) (45). After experimental deletion of one viral PKR inhibitor, the viral genome population developed an accordion-like expansion of the other inhibitor (Fig. 2B). Variations then arose and were positively selected in the extra copies of this PKR antagonist. These variants tended to remain in the progeny viral population even when the accordion-like gene array collapsed. The examination of genome content after each round of viral replication in culture revealed the existence of these intermediates in viral evolution. These data raise the intriguing question of whether similar mechanisms could occur in herpesviruses. Further investigation of herpesvirus adaptation to selective pressure, with analyses performed at frequent intervals throughout positive selection, will be required to test whether intermediates of viral evolution can be detected for herpesviruses as well.

HOST-VIRUS HORIZONTAL GENE TRANSFER

Horizontal gene transfer (HGT), or the movement of genetic material between unrelated organisms, provides another avenue for evolutionary adaptation. In the case of herpesviruses, at least 20% of the core genes shared by all herpesvirus subfamilies are surmised to have cellular origins, while others appear to have originated in another viral species (46–50). The specific source, mechanism, and timing of these ancient HGT events in herpesvirus evolutionary history are not known. Most herpesviruses do not integrate into the host genome during replication. The gamma-herpesvirus EBV can be found occasionally in an integrated state, although it is not a required aspect of its life cycle (51, 52). However, human HHV-6A and HHV-6B and Marek's disease virus, an alpha-herpesvirus of poultry, do integrate into host telomeres as a regular part of their life cycle (53–56). The germ line or chromosomal integration of human herpesviruses (ciHHV), usually HHV6A, is detected in about 1% of the human population (51, 53–56). Recent data from baculovirus-moth model systems indicate that HGT between host and virus does not require viral integration and excision from the host genome (57, 58). Instead, Gilbert et al. found that HGT can be mediated by transposable elements (TEs) that move between host and viral genomes (57) and that recombination of host DNA into viral progeny can occur at sites of microhomology between the host and viral genomes (58). Baculovirus genomes with integrated host DNA constituted only about 5% of the viral progeny and did not remain in the population beyond a few cycles of replication, suggesting that these are transient intermediates with deleterious fitness

effects (58). Nonetheless, these data illustrate a potential avenue for evolutionary HGT in nonintegrating viruses and suggest that it may be of interest to screen for signs of host DNA integration into progeny herpesvirus genomes.

OTHER CONTRIBUTIONS TO FUNCTIONAL DIVERSITY

Mechanisms of genetic variation such as single-nucleotide changes, recombination, and horizontal gene transfer are well accepted for their roles in the evolution of herpesviruses. Limited but exciting data suggest that other mechanisms, including several that are more often associated with RNA viruses, may also contribute to the diversity of herpesvirus coding potential. These include ribosome slippage, RNA editing, and novel transcripts revealed by RNA sequencing (RNA-Seq) and ribosome profiling or footprinting. These mechanisms may not be revealed by examining populations of viral genomes but may nonetheless influence phenotypes observed *in vivo*.

Ribosome frameshifting and RNA editing are two mechanisms by which herpesviruses can achieve a phenotypic outcome different from the outcome that would be predicted by analysis of the nucleotides encoded in their genome. These outcomes can be detected by examining viral transcripts or proteins but may otherwise go undetected in the comparison of genome sequences. Ribosome frameshifting is a regular feature of translation for retroviruses such as HIV, where it enables the production of nucleocapsid and polymerase from the same RNA transcript. Although it is less frequent, ribosome frameshifting has been demonstrated to occur on transcripts of thymidine kinase (TK) in HSV-1 (59, 60). Microdeletions at homopolymers in the TK or polymerase genes of HSV-1 are a common route of viral escape from the activity of the antiviral drug acyclovir (61, 62), and ribosome frameshifting of defective transcripts in these drug-resistant genomes allows production of a low level of functional protein (59, 60). RNA editing or transcriptional stuttering is another mechanism better associated with RNA viruses which is used to generate more than one transcript from a single open reading frame. RNA editing has recently been demonstrated to occur in the gamma-herpesviruses EBV and KSHV, where it affects microRNAs (EBV) or viral protein-coding genes (KSHV) (63, 64). The phenotypic impacts of these RNA editing events remain to be determined.

Finally, HTS approaches have highlighted the presence of previously unrecognized coding potential in herpesvirus genomes, through the use of RNA-Seq and ribosome profiling approaches that demonstrate the shift from host to viral transcriptional and translational control during infection (64–68). These approaches have illuminated new transcripts and coding potential in HCMV, EBV, and KSHV (64–67) and demonstrated the disruption of transcript termination in HSV-1 (68). The novel transcripts found in these studies are too new to have been considered in prior comparative genomics analyses, but future studies may reveal their influence on the biology and evolution of these herpesviruses.

CAPTURING AND CATALOGING THE DIVERSITY OF HERPESVIRUSES

Early applications of HTS to herpesvirus genomes focused on just one or two examples of a given species (69), using viral strains that had been previously characterized in cell culture. The norm for HTS studies has now shifted to include either comparisons of a large number of viral strains at a time or a deeper investigation of viral setting or outbreak. This expansion of known diversity has driven the definition of new phylogenetic clades and facilitated the reconstruction of the evolutionary history of VZV (28, 30–32), HSV-1 (23, 36, 70–72), HSV-2 (73–76), HCMV (20, 33, 34, 77), HHV 6A/6B (119), EBV (78, 79), and KSHV (80), as well as animal herpesviruses (41). While it is clear that increasing the number of fully sequenced genomes for each species widens our knowledge of viral diversity, the next challenge lies in dissecting the phenotypic impacts of the observed genetic differences in these viral populations. Achieving that goal will require the integration of phenotypic measures of viral fitness, with fully sequenced viruses and comparative genomics, to infer how specific genetic differences influence the outcome of infection.




FIG 2 Viral genomes with subtle variations contribute to the overall viral population and enable change over time. A viral population may contain minor variants (A) that remain unnoticed until selective pressures or bottlenecks reveal them (B). Deep sequencing approaches can reveal minor variants in the overall viral population, but most HTS approaches report only the consensus genome population. The consensus genome is a summary of the most common variants (e.g., those indicated by orange and blue stars) found in a majority of the sequenced genomes, but that exact genotype does not necessarily predominate in nature. As shown in the exaggerated example in panel A, the consensus genome (thick gray line) contains variants that are found in the majority of genomes (thin gray lines) but that are found only rarely in the same genome. Minor variants or alleles (e.g., those indicated by green or orange stars) are not included in the consensus genome at all, but a transmission bottleneck or subsequent selective pressure may lead to a minor variant becoming the majority genotype in the future (B). Recombination can also create entirely new genotypes, which can become dominant through bottlenecks or external selective pressures. Gene accordions, as demonstrated in vaccinia virus, result from expansion and subsequent variation of a gene under strong selective pressure.

As the genomic comparison of large DNA viruses from cultured stocks became more tractable, the goal of achieving similar resolution from uncultured viruses became a priority. The development of oligonucleotide enrichment methods has facilitated this goal for herpesviruses (29, 37, 77, 81). Oligonucleotide enrichment uses the known genomes of cultured viruses to design small RNA- or DNA-based probes or baits that can hybridize with sparse amounts of the targeted viral genomes in any mixed sample. These hybridized fragments are then isolated using a tag such as biotin on the synthetic oligonucleotide baits. Once enriched from a mixed source sample, the viral genome fragments can be amplified and sequenced using standard HTS approaches. Oligonucleotide enrichment has enabled the capture of herpesvirus genomes from saliva, blood, skin swabs, vesicle fluid, and more (29, 37, 81). Improvements in the isolation and handling of ancient DNA, combined with oligonucleotide enrichment, have even demonstrated the feasibility of recovering historical samples, such as the recent genome sequencing of 17th century smallpox (variola) DNA from mummified human remains (82). This type of ancient viral genome recovery has not yet been attempted for a herpesvirus, but if the challenge is surmounted it may similarly illuminate the rate of evolution and local adaptation seen in these viruses.

THE CONSENSUS VERSUS THE MINORITY

Many of the studies described above that catalogued herpesvirus diversity have focused on defining the consensus genome of each new sample. The consensus genome represents the most common allele or nucleotide at each position (Fig. 2). In the simplest case, the consensus genome is derived from the most common member of the viral population. However, the consensus genome may not exist in nature as the most common genome format—in other words, it may be an amalgamation of several genotypes that exist separately but not together on a single genome (Fig. 2A). For small viruses, the ability to clone and determine the genotypes of individual genomes has enabled the modeling of viral populations and the development of software that can infer likely haplotypes from HTS data (see reference 83 for a review). Barcoded HTS methods offer the potential to improve haplotype linking for large DNA viruses, but these have not yet been widely applied to human herpesviruses. Thus far, no HTS method has proven capable of sequencing individual strands of DNA viruses that are >100 kb in length

with sufficient accuracy and reproducibility to make enable the comparison of individual genomes in a viral population. Limited applications of nanopore-based sequencing (MinION; Oxford Nanopore) or single-molecule real-time sequencing (SMRT; Pacific Biosystems) to herpesviruses have demonstrated the potential of these methods (71, 84, 85). However, both technologies currently suffer from error-prone sequence reads, leading to limited applications during this phase of technical development. For these reasons, most researchers using Illumina or other short-read HTS platforms have focused on detecting the location and prevalence of minority variants, without attempting to link their co-occurrence on individual genomes (i.e., determining haplotypes).

As for RNA virus genomes, deep coverage of large DNA virus genomes has enabled the detection of minority variants, or heterogeneous alleles, and their potential expansion in different environments (Fig. 2). It was recently demonstrated that bottlenecks and selective sweeps occur during human congenital infection by the beta-herpesvirus HCMV. In a series of papers, Renzette et al. showed that HCMV genomes sequenced from the urine of congenitally infected infants harbored multiple loci with minority variants (17–19). While the authors initially posited that HCMV diversity approached the level of a quasispecies, their subsequent modeling suggested that viral diversity in these congenitally infected infants resulted from a combination of sources such as reinfection, recombination, positive selection, and bottlenecks during intrahost transmission between body sites (19, 86, 87) (Fig. 2B). Other groups have found a lower level of intrahost diversity in the context of noncongenital HCMV infections (16, 20, 33, 34, 77), suggesting that congenital infections may represent a special case for viral diversification. Recently, HTS was applied to detect low-frequency drug resistance mutations in the HCMV genome, which has confirmed the potential impacts of intrahost viral diversity on clinically important outcomes such as drug resistance (20). Although the study was conducted retrospectively, after patient treatment, the potential application for real-time HTS screening of viral populations during patient treatment is clear (88, 89).

VIRAL ISOLATES, STRAINS, VARIANTS, AND SUBCLONES

HTS methods have brought the issue of viral population diversity to the fore. Almost all experiments conducted with herpesviruses utilize a population of genome-containing virions (Fig. 2). The same is true of most samples collected from a host source. Because viral populations can shift over time or through handling (Fig. 1), it is crucial to clearly define each viral population under study and to know its history (24). A virus collected from a point source at a specific time is often called an isolate, and it may be referred to as a strain after its growth and expansion in culture. Even after being established as a strain in cell culture, a viral population may still undergo further change (Fig. 1). This can occur through random genetic drift, during intentional bottlenecks such as plaque purification, or through the generation of transgenic or mutant subclones. A viral strain can thus consist of a mixed population of viruses, or it may have undergone a bottleneck that led to the creation of a homogeneous population. For instance, the HSV-1 strain KOS has developed variants by genetic drift over passages in culture, as well as through intentional plaque purification of subclones (25, 90–94). These variants and subclones differ in observable phenotypes such as their ability to elicit Toll-like-receptor (TLR)-dependent immune responses (93), pathogenesis in animal models of HSV encephalitis (91), and expression of antigenic proteins (90, 92). This example emphasizes the importance of knowing the identity and history of the viral populations used in all laboratory experiments.

A more consistent standard of description for viral populations would benefit the herpesvirus community. Descriptive terms such as “clinical isolate” and “laboratory strain” are often used to refer to the low (clinical) versus high (laboratory strain) number of passages that a viral population has undergone in cell culture—though in practice these terms are interpreted differently by every research group (5, 24). There is no historical standard for whether or not a herpesvirus isolate should be plaque purified before it can be called a strain. There is no common term used to describe viral genomes that are collected and sequenced directly from a host, without amplification

in culture—these are often referred to simply as genomes, sequences, or genotypes (29, 75, 77, 95). The VZV research community and others have moved toward a viral naming system, akin to those utilized for RNA viruses and bacteria, which includes both virus species and host species and preserves data on sample origin (e.g., geographic location), year of isolation, and the name(s) of the strain, variant, or subclone (96, 97). Following on the HSV-1 KOS example above, one variant of the strain is named HSV-1 *Homo sapiens/Texas, USA/1963/KOS-KOS63*, indicating both the year and location of its origin (25, 94). This approach may help to alleviate current issues in comparing data across laboratories, where viruses of the same common name (e.g., HSV-1 KOS or HCMV AD169) may differ in both genotype and phenotype (24, 25, 94).

BIOINFORMATICS AND THE FOUNDATION OF HIGH-QUALITY GENOMES

The ability to rapidly sequence and assemble large DNA virus genomes has been facilitated by advances in software and computational workflows, although the diversity of options and different standards of publication have led to a wide variety of finished-genome qualities. One major choice underlying all HTS genome analysis is whether to build new viral genomes by alignment of reads to a prior reference genome or by *de novo* assembly. Alignment-based approaches utilize prior genome knowledge to achieve a faster outcome, but these are prone to miscalling of minority and structural variants (83). *De novo* assembly is unbiased by prior data and can more easily detect new variants and structural differences, but it is more computationally intensive and can entail the need for more input to curate the genomes thereafter (83). Open-source options for viral genome analysis and annotation include Web-based platforms and those using command-line (Unix-like) interfaces. The vast majority of viral *de novo* assembly algorithms have been developed and tested only for RNA viruses (see reference 83 for a review of options). We developed the Web-based viral *de novo* assembly workflow VirAmp specifically for herpesviruses (98), using the Galaxy framework of Web-accessible bioinformatics tools (99, 100). Most other options for viral genome assembly, alignment, annotation, and comparison rely on a Unix command-line interface, which requires more skill to operate. Unix-based software options are freely available through repositories such as BitBucket and GitHub and include programs such as the *de novo* viral genome assembly workflow VirGA (23), the aligners Bowtie and BWA (83), and the structural variant detector Wham (101). Researchers can also choose from commercial packages that offer one-button solutions for alignment or *de novo* assembly, such as Geneious (Biomatters) and CLC Bio (Qiagen) (99, 100). These options have made complex bioinformatics tasks accessible to a wider audience, to the extent that whole-genome sequencing and comparisons of diverse bacteriophage are now part of the undergraduate science education curriculum at many universities (102, 103).

The rationale for a strong foundation of high-quality genomes has been well established by the human genome project and multiple microbial genome projects (104). A wide range of secondary HTS applications, such as RNA-Seq, ribosome profiling, chromatin-immunoprecipitation (ChIP) sequencing, and chromatin conformation capture (CCC or 3C) assays, rely on the accuracy of initial genome sequences (105). Use of a misassembled or poorly annotated viral genome leads to errors in these secondary analyses. Similarly, mapping data from downstream analyses of one viral strain onto the reference genome of another strain can produce misleading outcomes. Gaps or unfinished regions in genome assemblies also create an issue, since these create missing data in all subsequent comparative genomics approaches. Publications occasionally omit the deposition of intact genome sequences, limiting future comparisons of these data (35, 71, 106). The failure to complete the sequence of genes with complex tandem repeats or G/C-rich sequences means that these genes are often excluded from comparative genomics studies or are represented by a far smaller number of examples (see, for example, references 36, 73, 75, and 107). Incomplete intergenic regions can skew the assessment of overall genomic diversity, since genetic drift tends to accumulate in intergenic regions. Unresolved gaps also prohibit any insight from secondary analyses such as RNA-Seq or ChIP in these regions, since data cannot be mapped to these areas. The tremendous insights to be gained from HTS technologies and all of

their secondary applications thus rely on a strong foundation in the initial deciphering of viral genome populations.

FUTURE DIRECTIONS

Here we have focused on the several areas of recent progress in understanding the genomic diversity and evolution of human herpesviruses. These advances have been driven by the rapid expansion and application of HTS, bioinformatics, and comparative genomics in virology. Together, these data have reshaped our sense of the stability of herpesvirus genomes. While these viruses possess high-fidelity polymerases, their ability to accrue standing variation, and to undergo recombination with neighboring genomes, creates many opportunities for selective pressures to induce rapid genetic shifts. Examples of this include the expansion of minority variants in niche locations in congenitally infected infants and the selection of drug-resistant variants during antiviral therapy (16, 19, 20, 86). In addition to these recent advances and insights, we foresee several areas of future promise.

First, we foresee the improvement and extension of third-generation sequencing and genome editing technologies to herpesviruses. Early applications of MinION and SMRT long-read sequencing to herpesvirology have shown promise in revealing novel transcriptional networks (67, 85) and in confirming a new synthetic genome approach to introduce multiple simultaneous changes to a herpesvirus genome (84). These third-generation sequencing methods may also enable the detection of methylated bases, secondary structures, and even substrates besides DNA (105). As the accuracy of these methods improves, we foresee their use to advance the detection of recombinant genomes and structural variants, as well as to define haplotypes in mixed populations (Fig. 2). The advances in clustered regularly interspaced short palindromic repeat (CRISPR)-Cas systems for genetic engineering of herpesviruses also represent an exciting area for future expansion (108–110). CRISPR-Cas approaches promise to speed the construction of viral mutants for reverse genetic studies (108, 109) and may have therapeutic potential for herpesvirus genome clearance (110). We also anticipate that HTS and genomic analyses of CRISPR-engineered viruses will be a fruitful way to confirm the desired genomic edits and rule out any off-target or bystander changes.

Finally, we consider the linking of viral genetic variation to observable phenotypes to be one of the greatest challenges for virology. The advance of HTS and genomics has begun to enable the application of genome-wide association studies (GWAS) and quantitative trait locus (QTL) approaches to herpesviruses (111, 112). Brandt and colleagues recently demonstrated the application of viral QTL mapping to HSV-1, by examining how specific viral genotypes contributed to phenotypes of ocular infection in mice (113, 114). That QTL study used the recombinant viral progeny of two attenuated strains of HSV-1, with the differing genetic composition of each recombinant being mapped to the nucleotide resolution level using HTS and comparative genomics (27). These forward genetic approaches complement prior decades of reverse genetic approaches, which established the function of herpesvirus genes and began to dissect the impacts of individual genetic variants (115, 116). However, the occurrence of gene deletions and genetic variations in living humans can be quite distinct from those seen in laboratory-constructed mutants (33, 75, 78), and there is significant interest in determining if and how these viral genetic variants may impact human clinical outcomes (79, 117, 118). This motivates the future extension of GWAS analyses to naturally circulating viral variants and clinical isolates. This will shed light on how viral genetic diversity intersects with human genetic differences to produce the spectrum of observed disease.

ACKNOWLEDGMENTS

We acknowledge the many contributions of scientists whose work could not be cited here for space reasons. Their intellectual contributions shaped our work and this summary. We thank our reviewers, members of the Szpara laboratory, and our many colleagues for insightful conversations and feedback.

We acknowledge support from the Eberly College of Science and the Huck Institutes for

the Life Sciences at the Pennsylvania State University (M.L.S.). This project was funded, in part, under a grant with the Pennsylvania Department of Health using Tobacco CURE funds (M.L.S.). The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions presented in this report.

REFERENCES

1. Looker KJ, Magaret AS, May MT, Turner KME, Vickerman P, Gottlieb SL, Newman LM. 2015. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. *PLoS One* 10:e0140765. <https://doi.org/10.1371/journal.pone.0140765>.
2. Looker KJ, Magaret AS, Turner KME, Vickerman P, Gottlieb SL, Newman LM. 2015. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. *PLoS One* 10:e114989. <https://doi.org/10.1371/journal.pone.0114989>.
3. Jansen MAE, van den Heuvel D, Bouthoorn SH, Jaddoe VWV, Hooijkaas H, Raat H, Fraaij PLA, van Zelm MC, Moll HA. 2016. Determinants of ethnic differences in cytomegalovirus, Epstein-Barr virus, and herpes simplex virus type 1 seroprevalence in childhood. *J Pediatr* 170:126–134.e6. <https://doi.org/10.1016/j.jpeds.2015.11.014>.
4. Gantt S, Orem J, Krantz EM, Morrow RA, Selke S, Huang M-L, Schiffer JT, Jerome KR, Nakaganda A, Wald A, Casper C, Corey L. 24 February 2016. Prospective characterization of the risk factors for transmission and symptoms of primary human herpesvirus infections among Ugandan infants. *J Infect Dis* <https://doi.org/10.1093/infdis/jiw076>.
5. Davison AJ. 2010. Herpesvirus systematics. *Vet Microbiol* 143:52–69. <https://doi.org/10.1016/j.vetmic.2010.02.014>.
6. Koonin EV, Krupovic M, Yutin N. 2015. Evolution of double-stranded DNA viruses of eukaryotes: from bacteriophages to transposons to giant viruses: Evolution of dsDNA viruses of eukaryotes. *Ann N Y Acad Sci* 1341:10–24. <https://doi.org/10.1111/nyas.12728>.
7. Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R. 2010. Viral mutation rates. *J Virol* 84:9733–9748. <https://doi.org/10.1128/JVI.00694-10>.
8. Sanjuán R, Domingo-Calap P. 2016. Mechanisms of viral mutation. *Cell Mol Life Sci* 73:4433–4448. <https://doi.org/10.1007/s00018-016-2299-6>.
9. Hall JD, Almy RE. 1982. Evidence for control of herpes simplex virus mutagenesis by the viral DNA polymerase. *Virology* 116:535–543. [https://doi.org/10.1016/0042-6822\(82\)90146-5](https://doi.org/10.1016/0042-6822(82)90146-5).
10. Drake JW, Hwang CBC. 2005. On the mutation rate of herpes simplex virus type 1. *Genetics* 170:969–970. <https://doi.org/10.1534/genetics.104.040410>.
11. Drake JW. 1991. A constant rate of spontaneous mutation in DNA-based microbes. *Proc Natl Acad Sci U S A* 88:7160–7164. <https://doi.org/10.1073/pnas.88.16.7160>.
12. Sakaoka H, Kurita K, Iida Y, Takada S, Umene K, Kim YT, Ren CS, Nahmias AJ. 1994. Quantitative analysis of genomic polymorphism of herpes simplex virus type 1 strains from six countries: studies of molecular evolution and molecular epidemiology of the virus. *J Gen Virol* 75:513–527. <https://doi.org/10.1099/0022-1317-75-3-513>.
13. Sarisky RT, Nguyen TT, Duffy KE, Wittrock RJ, Leary JJ. 2000. Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2. *Antimicrob Agents Chemother* 44:1524–1529. <https://doi.org/10.1128/AAC.44.6.1524-1529.2000>.
14. Renzette N, Gibson L, Jensen JD, Kowalik TF. 2014. Human cytomegalovirus intrahost evolution—a new avenue for understanding and controlling herpesvirus infections. *Curr Opin Virol* 8:109–115. <https://doi.org/10.1016/j.coviro.2014.08.001>.
15. Firth C, Kitchen A, Shapiro B, Suchard MA, Holmes EC, Rambaut A. 2010. Using time-structured data to estimate evolutionary rates of double-stranded DNA viruses. *Mol Biol Evol* 27:2038–2051. <https://doi.org/10.1093/molbev/msq088>.
16. Görzer I, Guelly C, Trajanoski S, Puchhammer-Stöckl E. 2010. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. *J Virol* 84:7195–7203. <https://doi.org/10.1128/JVI.00475-10>.
17. Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF. 19 May 2011. Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. *PLoS Pathog* <https://doi.org/10.1371/journal.ppat.1001344>.
18. Renzette N, Gibson L, Bhattacharjee B, Fisher D, Schleiss MR, Jensen JD, Kowalik TF. 26 September 2013. Rapid intrahost evolution of human cytomegalovirus is shaped by demography and positive selection. *PLoS Genet* <https://doi.org/10.1371/journal.pgen.1003735>.
19. Renzette N, Pokalyuk C, Gibson L, Bhattacharjee B, Schleiss MR, Hamprecht K, Yamamoto AY, Mussi-Pinhata MM, Britt WJ, Jensen JD, Kowalik TF. 6 July 2015. Limits and patterns of cytomegalovirus genomic diversity in humans. *Proc Natl Acad Sci U S A* <https://doi.org/10.1073/pnas.1501880112>.
20. Houldcroft CJ, Bryant JM, Depledge DP, Margetts BK, Simmonds J, Nicolaou S, Tutil HJ, Williams R, Worth AJ, Marks SD, Veys P, Whittaker E, Breuer J. 9 September 2016. Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus. *Front Microbiol* <https://doi.org/10.3389/fmicb.2016.01317>.
21. Jaramillo N, Domingo E, Munoz-Egea MC, Tabares E, Gadea I. 2013. Evidence of Muller's ratchet in herpes simplex virus type 1. *J Gen Virol* 94:366–375. <https://doi.org/10.1099/vir.0.044685-0>.
22. Bradley AJ, Lurain NS, Ghazal P, Trivedi U, Cunningham C, Baluchova K, Gatherer D, Wilkinson GWG, Dargan DJ, Davison AJ. 2009. High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. *J Gen Virol* 90:2375–2380. <https://doi.org/10.1099/vir.0.013250-0>.
23. Parsons LR, Tafuri YR, Shreve JT, Bowen CD, Shipley MM, Enquist LW, Szpara ML. 2015. Rapid genome assembly and comparison decode intrastrain variation in human alphaherpesviruses. *mBio* 6:e02213-14. <https://doi.org/10.1128/mBio.02213-14>.
24. Wilkinson GWG, Davison AJ, Tomasec P, Fielding CA, Aicheler R, Murrell I, Seirafian S, Wang ECY, Weekes M, Lehner PJ, Wilkie GS, Stanton RJ. 2015. Human cytomegalovirus: taking the strain. *Med Microbiol Immunol* 204:273–284. <https://doi.org/10.1007/s00430-015-0411-4>.
25. Bowen CD, Renner DW, Shreve JT, Tafuri Y, Payne KM, Dix RD, Kinchington PR, Gatherer D, Szpara ML. 2016. Viral forensic genomics reveals the relatedness of classic herpes simplex virus strains KOS, KOS63, and KOS79. *Virology* 492:179–186. <https://doi.org/10.1016/j.virol.2016.02.013>.
26. Greenbaum BD, Ghedin E. 2015. Viral evolution: beyond drift and shift. *Curr Opin Microbiol* 26:109–115. <https://doi.org/10.1016/j.mib.2015.06.015>.
27. Lee K, Kolb AW, Sverchokov Y, Cuellar JA, Craven M, Brandt CR. 2015. Recombination analysis of herpes simplex virus 1 reveals a bias toward GC content and the inverted repeat regions. *J Virol* 89:7214–7223. <https://doi.org/10.1128/JVI.00880-15>.
28. Zell R, Taudien S, Pfaff F, Wutzler P, Platzer M, Sauerbrei A. 2012. Sequencing of 21 varicella-zoster virus genomes reveals two novel genotypes and evidence of recombination. *J Virol* 86:1608–1622. <https://doi.org/10.1128/JVI.06233-11>.
29. Depledge DP, Gray ER, Kundu S, Cooray S, Poulsen A, Aaby P, Breuer J. 2014. Evolution of cocirculating varicella-zoster virus genotypes during a chickenpox outbreak in Guinea-Bissau. *J Virol* 88:13936–13946. <https://doi.org/10.1128/JVI.02337-14>.
30. Norberg P, Depledge DP, Kundu S, Atkinson C, Brown J, Haque T, Hussaini Y, MacMahon E, Molyneaux P, Papaevangelou V, Sengupta N, Koay ESC, Tang JW, Underhill GS, Grahm A, Studahl M, Breuer J, Bergström T. 2015. Recombination of globally circulating varicella-zoster virus. *J Virol* 89:7133–7146. <https://doi.org/10.1128/JVI.00437-15>.
31. Jeon JS, Won YH, Kim IK, Ahn JH, Shin OS, Kim JH, Lee CH. 2016. Analysis of single nucleotide polymorphism among varicella-zoster virus and identification of vaccine-specific sites. *Virology* 496:277–286. <https://doi.org/10.1016/j.virol.2016.06.017>.
32. Jensen NJ, Rivaller P, Tseng HF, Quinlivan ML, Radford K, Folster J, Harpaz R, LaRussa P, Jacobsen S, Scott Schmid D. 2017. Revisiting the genotyping scheme for varicella-zoster viruses based on whole-genome comparisons. *J Gen Virol* 98:1434–1438. <https://doi.org/10.1099/jgv.0.000772>.
33. Sijmons S, Thys K, Mbong Ngwese M, Van Damme E, Dvorak J, Van Loock M, Li G, Tachezy R, Busson L, Aerssens J, Van Ranst M, Maes P.

2015. High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination. *J Virol* 89:7673–7695. <https://doi.org/10.1128/JVI.00578-15>.
34. Lassalle F, Depledge DP, Reeves MB, Brown AC, Christiansen MT, Tutill HJ, Williams RJ, Einer-Jensen K, Holdstock J, Atkinson C, Brown JR, van Loenen FB, Clark DA, Griffiths PD, Verjans GMGM, Schutten M, Milne RSB, Balloux F, Breuer J. 2016. Islands of linkage in an ocean of pervasive recombination reveals two-speed evolution of human cytomegalovirus genomes. *Virus Evol* 2:vew017. <https://doi.org/10.1093/ve/vew017>.
 35. Norberg P, Tyler S, Severini A, Whitley R, Liljeqvist JÅ, Bergström T. 25 July 2011. A genome-wide comparative evolutionary analysis of herpes simplex virus type 1 and varicella zoster virus. *PLoS One* <https://doi.org/10.1371/journal.pone.0022527>.
 36. Szpara ML, Gatherer D, Ochoa A, Greenbaum B, Dolan A, Bowden RJ, Enquist LW, Legendre M, Davison AJ. 2014. Evolution and diversity in human herpes simplex virus genomes. *J Virol* 88:1209–1227. <https://doi.org/10.1128/JVI.01987-13>.
 37. Koelle DM, Norberg P, Fitzgibbon MP, Russell RM, Greninger AL, Huang M-L, Stensland L, Jing L, Magaret AS, Diem K, Selke S, Xie H, Celum C, Lingappa JR, Jerome KR, Wald A, Johnston C. 2017. Worldwide circulation of HSV-2 × HSV-1 recombinant strains. *Sci Rep* 7:44084. <https://doi.org/10.1038/srep44084>.
 38. Burrell S, Boutolleau D, Ryu D, Agut H, Merkel K, Leendertz FH, Calvignac-Spencer S. 2017. Ancient recombination events between human herpes simplex viruses. *Mol Biol Evol* 34:1713–1721. <https://doi.org/10.1093/molbev/msx113>.
 39. Burrell S, Désiré N, Marlet J, Dacheux L, Seang S, Caumes E, Bourhy H, Agut H, Boutolleau D. 2015. Genetic diversity within alpha herpesviruses: characterization of a novel variant of herpes simplex virus 2. *J Virol* 89:12273–12283. <https://doi.org/10.1128/JVI.01959-15>.
 40. Wertheim JO, Smith DM, Scheffler K, Pong SLK. 10 July 2014. Evolutionary origins of human herpes simplex viruses 1 and 2. *Mol Biol Evol* <https://doi.org/10.1093/molbev/msu185>.
 41. Loncoman CA, Vaz PK, Coppo MJ, Hartley CA, Morera FJ, Browning GF, Devlin JM. 2017. Natural recombination in alpha herpesviruses: insights into viral evolution through full genome sequencing and sequence analysis. *Infect Genet Evol* 49:174–185. <https://doi.org/10.1016/j.meegid.2016.12.022>.
 42. Lee S-W, Markham PF, Coppo MJC, Legione AR, Markham JF, Noormohammadi AH, Browning GF, Ficorilli N, Hartley CA, Devlin JM. 2012. Attenuated vaccines can recombine to form virulent field viruses. *Science* 337:188–188. <https://doi.org/10.1126/science.1217134>.
 43. Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, Jarvis MA, Hahn G, Nelson JA, Myers RM, Shenk TE. 2003. Coding potential of laboratory and clinical strains of human cytomegalovirus. *Proc Natl Acad Sci U S A* 100:14976–14981. <https://doi.org/10.1073/pnas.2136652100>.
 44. Boyer M, Azza S, Barrassi L, Klose T, Campocasso A, Pagnier I, Fournous G, Borg A, Robert C, Zhang X, Desnues C, Henrissat B, Rossmann MG, La Scola B, Raoult D. 2011. Mimivirus shows dramatic genome reduction after intraoocytic culture. *Proc Natl Acad Sci U S A* 108:10296–10301. <https://doi.org/10.1073/pnas.1101181108>.
 45. Elde NC, Child SJ, Eickbush MT, Kitzman JO, Rogers KS, Shendure J, Geballe AP, Malik HS. 2012. Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses. *Cell* 150:831–841. <https://doi.org/10.1016/j.cell.2012.05.049>.
 46. Alcami A. 2003. Viral mimicry of cytokines, chemokines and their receptors. *Nat Rev Immunol* 3:36–50. <https://doi.org/10.1038/nri980>.
 47. McGeoch DJ, Davison AJ, Dolan A, Gatherer D, Sevilla-Reyes EE. 2008. Molecular evolution of the Herpesvirales, p 447–475. *In* Origin and evolution of viruses. Elsevier, Philadelphia, PA.
 48. Elde NC, Malik HS. 2009. The evolutionary conundrum of pathogen mimicry. *Nat Rev Microbiol* 7:787–797. <https://doi.org/10.1038/nrmicro2222>.
 49. Rappoport N, Linal M. 2012. Viral proteins acquired from a host converge to simplified domain architectures. *PLoS Comput Biol* 8:e1002364. <https://doi.org/10.1371/journal.pcbi.1002364>.
 50. Aswad A, Katzourakis A. 2015. Convergent capture of retroviral superantigens by mammalian herpesviruses. *Nat Commun* 6:8299. <https://doi.org/10.1038/ncomms9299>.
 51. Morissette G, Flamand L. 2010. Herpesviruses and chromosomal integration. *J Virol* 84:12100–12109. <https://doi.org/10.1128/JVI.01169-10>.
 52. Xiao K, Yu Z, Li X, Li X, Tang K, Tu C, Qi P, Liao Q, Chen P, Zeng Z, Li G, Xiong W. 2016. Genome-wide analysis of Epstein-Barr virus (EBV) integration and strain in C666-1 and Raji cells. *J Cancer* 7:214–224. <https://doi.org/10.7150/jca.13150>.
 53. Kauffer BB, Jarosinski KW, Osterrieder N. 2011. Herpesvirus telomeric repeats facilitate genomic integration into host telomeres and mobilization of viral DNA during reactivation. *J Exp Med* 208:605–615. <https://doi.org/10.1084/jem.20101402>.
 54. Osterrieder N, Wallaschek N, Kauffer BB. 2014. Herpesvirus genome integration into telomeric repeats of host cell chromosomes. *Annu Rev Virol* 1:215–235. <https://doi.org/10.1146/annurev-virology-031413-085422>.
 55. Wallaschek N, Sanyal A, Pirzer F, Gravel A, Mori Y, Flamand L, Kauffer BB. 2016. The telomeric repeats of human herpesvirus 6A (HHV-6A) are required for efficient virus integration. *PLoS Pathog* 12:e1005666. <https://doi.org/10.1371/journal.ppat.1005666>.
 56. Tweedy J, Spyrou M, Pearson M, Lassner D, Kuhl U, Gompels U. 2016. Complete genome sequence of germline chromosomally integrated human herpesvirus 6A and analyses integration sites define a new human endogenous virus with potential to reactivate as an emerging infection. *Viruses* 8:E19. <https://doi.org/10.3390/v8010019>.
 57. Gilbert C, Chateigner A, Ernenwein L, Barbe V, Bézier A, Herniou EA, Cordaux R. 21 February 2014. Population genomics supports baculoviruses as vectors of horizontal transfer of insect transposons. *Nat Commun* <https://doi.org/10.1038/ncomms4348>.
 58. Gilbert C, Peccoud J, Chateigner A, Moumen B, Cordaux R, Herniou EA. 2016. Continuous influx of genetic material from host to virus populations. *PLoS Genet* 12:e1005838. <https://doi.org/10.1371/journal.pgen.1005838>.
 59. Griffiths A, Chen S, Horsburgh BC, Coen DM. 2003. Translational compensation of a frameshift mutation affecting herpes simplex virus thymidine kinase is sufficient to permit reactivation from latency. *J Virol* 77:4703–4709. <https://doi.org/10.1128/JVI.77.8.4703-4709.2003>.
 60. Pan D, Coen DM. 2012. Net –1 frameshifting on a noncanonical sequence in a herpes simplex virus drug-resistant mutant is stimulated by nonstop mRNA. *Proc Natl Acad Sci U S A* 109:14852–14857. <https://doi.org/10.1073/pnas.1206582109>.
 61. Wang K, Mahalingam G, Hoover SE, Mont EK, Holland SM, Cohen JL, Straus SE. 2007. Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and ganglia. *J Virol* 81:6817–6826. <https://doi.org/10.1128/JVI.00166-07>.
 62. Burrell S, Deback C, Agut H, Boutolleau D. 2010. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. *Antimicrob Agents Chemother* 54:4833–4842. <https://doi.org/10.1128/AAC.00669-10>.
 63. Lin Z, Wang X, Strong MJ, Concha M, Baddoo M, Xu G, Baribault C, Fewell C, Hulme W, Hedges D, Taylor CM, Flemington EK. 2013. Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains. *J Virol* 87:1172–1182. <https://doi.org/10.1128/JVI.02517-12>.
 64. Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, Holdorf M, Weissman JS, Ganem D. 2014. KSHV 2.0: a comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. *PLoS Pathog* 10:e1003847. <https://doi.org/10.1371/journal.ppat.1003847>.
 65. Stern-Ginossar N, Weisburd B, Michalski A, Le VTK, Hein MY, Huang S-X, Ma M, Shen B, Qian S-B, Hengel H, Mann M, Ingolia NT, Weissman JS. 2012. Decoding human cytomegalovirus. *Science* 338:1088–1093. <https://doi.org/10.1126/science.1227919>.
 66. Tirosh O, Cohen Y, Shitrit A, Shani O, Le-Trilling VTK, Trilling M, Friedlander G, Tanenbaum M, Stern-Ginossar N. 2015. The transcription and translation landscapes during human cytomegalovirus infection reveal novel host-pathogen interactions. *PLoS Pathog* 11:e1005288. <https://doi.org/10.1371/journal.ppat.1005288>.
 67. O'Grady T, Wang X, Höner zu Bentrup K, Baddoo M, Concha M, Flemington EK. 2016. Global transcript structure resolution of high gene density genomes through multi-platform data integration. *Nucleic Acids Res* 44:e145–e145. <https://doi.org/10.1093/nar/gkw629>.
 68. Rutkowski AJ, Erhard F, L'Hernault A, Bonfert T, Schilhabel M, Crump C, Rosenstiel P, Efstathiou S, Zimmer R, Friedel CC, Dölken L. 2015. Widespread disruption of host transcription termination in HSV-1 infection. *Nat Commun* 6:7126. <https://doi.org/10.1038/ncomms8126>.
 69. Szpara ML, Parsons L, Enquist LW. 2010. Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations. *J Virol* 84:5303–5313. <https://doi.org/10.1128/JVI.00312-10>.
 70. Pfaff F, Groth M, Sauerbrei A, Zell R. 24 August 2015. Genotyping of

- herpes simplex virus type 1 (HSV-1) by whole genome sequencing. *J Gen Virol* <https://doi.org/10.1099/jgv.0.000589>.
71. Karamitros T, Harrison I, Piorkowska R, Katzourakis A, Magiorkinis G, Mbisa JL. 2016. De novo assembly of human herpes virus type 1 (HHV-1) genome, mining of non-canonical structures and detection of novel drug-resistance mutations using short- and long-read next generation sequencing technologies. *PLoS One* 11:e0157600. <https://doi.org/10.1371/journal.pone.0157600>.
 72. Petro CD, Weinrick B, Khajouejinejad N, Burn C, Sellers R, Jacobs WR, Herold BC. 4 August 2016. HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates. *JCI Insight* <https://doi.org/10.1172/jci.insight.88529>.
 73. Newman RM, Lamers SL, Weiner B, Ray SC, Colgrove RC, Diaz F, Jing L, Wang K, Saif S, Young S, Henn M, Laeyendecker O, Tobian AAR, Cohen JI, Koelle DM, Quinn TC, Knipe DM. 27 May 2015. Genome sequencing and analysis of geographically diverse clinical isolates of herpes simplex virus 2. *J Virol* <https://doi.org/10.1128/JVI.01303-15>.
 74. Kolb AW, Larsen IV, Cuellar JA, Brandt CR. 2015. Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains. *J Virol* 89:6427–6434. <https://doi.org/10.1128/JVI.00416-15>.
 75. Johnston C, Magaret A, Roychoudhury P, Greninger AL, Cheng A, Diem K, Fitzgibbon MP, Huang M, Selke S, Lingappa JR, Celum C, Jerome KR, Wald A, Koelle DM. 2017. Highly conserved intragenic HSV-2 sequences: results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents. *Virology* 510:90–98. <https://doi.org/10.1016/j.virol.2017.06.031>.
 76. Minaya MA, Jensen T, Goll J, Korom M, Datla SH, Belshe RB, Morrison LA. 20 September 2017. Molecular evolution of herpes simplex virus 2 complete genomes: comparison between primary and recurrent infections. *J Virol* <https://doi.org/10.1128/JVI.00942-17>.
 77. Hage E, Wilkie GS, Linnenweber-Held S, Dhingra A, Suárez NM, Schmidt JJ, Kay-Fedorov PC, Mischak-Weissinger E, Heim A, Schwarz A, Schulz TF, Davison AJ, Ganzenmueller T. 2017. Characterization of human cytomegalovirus genome diversity in immunocompromised hosts by whole-genome sequencing directly from clinical specimens. *J Infect Dis* 215:1673–1683. <https://doi.org/10.1093/infdis/jix157>.
 78. Palser AL, Grayson NE, White RE, Corton C, Correia S, Ba Abdullah MM, Watson SJ, Cotten M, Arrand JR, Murray PG, Allday MJ, Rickinson AB, Young LS, Farrell PJ, Kellam P. 2015. Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. *J Virol* 89:5222–5237. <https://doi.org/10.1128/JVI.03614-14>.
 79. Tu C, Zeng Z, Qi P, Li X, Yu Z, Guo C, Xiong F, Xiang B, Zhou M, Gong Z, Liao Q, Yu J, He Y, Zhang W, Li X, Li Y, Li G, Xiong W. 2017. Genome-wide analysis of 18 Epstein-Barr viruses isolated from primary nasopharyngeal carcinoma biopsy specimens. *J Virol* 91:e00301-17. <https://doi.org/10.1128/JVI.00301-17>.
 80. Olp LN, Jeanniard A, Marimo C, West JT, Wood C. 2015. Whole-genome sequencing of Kaposi's sarcoma-associated herpesvirus from Zambian Kaposi's sarcoma biopsy specimens reveals unique viral diversity. *J Virol* 89:12299–12308. <https://doi.org/10.1128/JVI.01712-15>.
 81. Depledge DP, Palser AL, Watson SJ, Lai IY-C, Gray ER, Grant P, Kanda RK, Leproust E, Kellam P, Breuer J. 2011. Specific capture and whole-genome sequencing of viruses from clinical samples. *PLoS One* 6:e27805. <https://doi.org/10.1371/journal.pone.0027805>.
 82. Duggan AT, Perdomo MF, Piombino-Mascalì D, Marciniak S, Poinar D, Emery MV, Buchmann JP, Duchêne S, Jankauskas R, Humphreys M, Golding GB, Southon J, Devault A, Rouillard J-M, Sahl JW, Dutour O, Hedman K, Sajantila A, Smith GL, Holmes EC, Poinar HN. 2016. 17th century variola virus reveals the recent history of smallpox. *Curr Biol* 26:3407–3412. <https://doi.org/10.1016/j.cub.2016.10.061>.
 83. Posada-Céspedes S, Seifert D, Beerenwinkel N. 28 September 2016. Recent advances in inferring viral diversity from high-throughput sequencing data. *Virus Res* <https://doi.org/10.1016/j.virusres.2016.09.016>.
 84. Oldfield LM, Grzesik P, Voorhies AA, Alperovich N, MacMath D, Najera CD, Chandra DS, Prasad S, Noskov VN, Montague MG, Friedman RM, Desai PJ, Vashee S. 19 September 2017. Genome-wide engineering of an infectious clone of herpes simplex virus type 1 using synthetic genomics assembly methods. *Proc Natl Acad Sci U S A* <https://doi.org/10.1073/pnas.1700534114>.
 85. Tombácz D, Csabai Z, Szűcs A, Balázs Z, Moldován N, Sharon D, Snyder M, Boldogkői Z. 20 June 2017. Long-read isoform sequencing reveals a hidden complexity of the transcriptional landscape of herpes simplex virus type 1. *Front Microbiol* <https://doi.org/10.3389/fmicb.2017.01079>.
 86. Renzette N, Kowalik TF, Jensen JD. 2016. On the relative roles of background selection and genetic hitchhiking in shaping human cytomegalovirus genetic diversity. *Mol Ecol* 25:403–413. <https://doi.org/10.1111/mec.13331>.
 87. Pokalyuk C, Renzette N, Irwin KK, Pfeifer SP, Gibson L, Britt WJ, Yamamoto AY, Mussi-Pinhata MM, Kowalik TF, Jensen JD. 8 February 2017. Characterizing human cytomegalovirus reinfection in congenitally infected infants: an evolutionary perspective. *Mol Ecol* <https://doi.org/10.1111/mec.13953>.
 88. Köser CU, Ellington MJ, Cartwright EJP, Gillespie SH, Brown NM, Farrington M, Holden MTG, Dougan G, Bentley SD, Parkhill J, Peacock SJ. 2012. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. *PLoS Pathog* 8:e1002824. <https://doi.org/10.1371/journal.ppat.1002824>.
 89. Houldcroft CJ, Beale MA, Breuer J. 2017. Clinical and biological insights from viral genome sequencing. *Nat Rev Microbiol* 15:183–192. <https://doi.org/10.1038/nrmicro.2016.182>.
 90. Holland TC, Marlin SD, Levine M, Glorioso J. 1983. Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies. *J Virol* 45:672–682.
 91. Dix RD, McKendall RR, Baringer JR. 1983. Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice. *Infect Immun* 40:103–112.
 92. Norberg P, Bergstrom T, Rekabdar E, Lindh M. 2004. Phylogenetic analysis of clinical herpes simplex virus type 1 isolates identified three genetic groups and recombinant viruses. *J Virol* 78:10755–10764. <https://doi.org/10.1128/JVI.78.19.10755-10764.2004>.
 93. Sato A, Linehan MM, Iwasaki A. 2006. Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. *Proc Natl Acad Sci U S A* 103:17343–17348. <https://doi.org/10.1073/pnas.0605102103>.
 94. Colgrove RC, Liu X, Griffiths A, Raja P, Deluca NA, Newman RM, Coen DM, Knipe DM. 2016. History and genomic sequence analysis of the herpes simplex virus 1 KOS and KOS1.1 sub-strains. *Virology* 487:215–221. <https://doi.org/10.1016/j.virol.2015.09.026>.
 95. Pandey U, Bell AS, Renner DW, Kennedy DA, Shreve JT, Cairns CL, Jones MJ, Dunn PA, Read AF, Szpara ML. 2016. DNA from dust: comparative genomics of large DNA viruses in field surveillance samples. *mSphere* 1:e00132-16. <https://doi.org/10.1128/mSphere.00132-16>.
 96. Breuer J, Grose C, Norberg P, Tipples G, Schmid DS. 2010. A proposal for a common nomenclature for viral clades that form the species varicellazoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24–25 July 2008. *J Gen Virol* 91:821–828. <https://doi.org/10.1099/vir.0.017814-0>.
 97. Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Hensley LE, Honko AN, Jahrling PB, Johnson KM, Kobinger G, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Saphire EO, Smither SJ, Swanepoel R, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Weidmann M, Nichol ST. 2013. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. *Arch Virol* 158:301–311. <https://doi.org/10.1007/s00705-012-1454-0>.
 98. Wan Y, Renner DW, Albert I, Szpara ML. 28 April 2015. VirAmp: a galaxy-based viral genome assembly pipeline. *GigaScience* <https://doi.org/10.1186/s13742-015-0060-y>.
 99. Giardine B, Riemer C, Hardison RC, Burhans R, Elnitski L, Shah P, Zhang Y, Blankenberg D, Albert I, Taylor J, Miller W, Kent WJ, Nekrutenko A. 2005. Galaxy: a platform for interactive large-scale genome analysis. *Genome Res* 15:1451–1455. <https://doi.org/10.1101/gr.4086505>.
 100. Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M, Nekrutenko A, Taylor J. 2010. Galaxy: a web-based genome analysis tool for experimentalists. *Curr Protoc Mol Biol* Chapter 19:Unit 19.10.1–21. <https://doi.org/10.1002/0471142727.mb1910s89>.
 101. Kronenberg ZN, Osborne EJ, Cone KR, Kennedy BJ, Domyan ET, Shapiro MD, Elde NC, Yandell M. 2015. Wham: identifying structural variants of biological consequence. *PLoS Comput Biol* 11:e1004572. <https://doi.org/10.1371/journal.pcbi.1004572>.
 102. Jordan TC, Burnett SH, Carson S, Caruso SM, Clase K, DeJong RJ, Dennehy JJ, Denver DR, Dunbar D, Elgin SCR, Findley AM, Gissendanner CR, Golebiewska UP, Guild N, Hartzog GA, Grillo WH, Hollowell GP, Hughes LE, Johnson A, King RA, Lewis LO, Li W, Rosenzweig F, Rubin MR, Saha MS, Sandoz J, Shaffer CD, Taylor B, Temple L, Vazquez E, Ware VC, Barker LP, Bradley KW, Jacobs-Sera D, Pope WH, Russell DA, Cresawn SG, Lopatto D, Bailey CP, Hatfull GF. 2014. A broadly implement-

- able research course in phage discovery and genomics for first-year undergraduate students. *mBio* 5:e01051-13. <https://doi.org/10.1128/mBio.01051-13>.
103. Hatfull GF, Racaniello V. 2014. PHIRE and *TWIV*: experiences in bringing virology to new audiences. *Annu Rev Virol* 1:37–53. <https://doi.org/10.1146/annurev-virology-031413-085449>.
 104. Fraser CM, Eisen JA, Nelson KE, Paulsen IT, Salzberg SL. 2002. The value of complete microbial genome sequencing (you get what you pay for). *J Bacteriol* 184:6403–6405. <https://doi.org/10.1128/JB.184.23.6403-6405.2002>.
 105. Reuter JA, Spacek DV, Snyder MP. 2015. High-throughput sequencing technologies. *Mol Cell* 58:586–597. <https://doi.org/10.1016/j.molcel.2015.05.004>.
 106. Danaher RJ, Fouts DE, Chan AP, Choi Y, DePew J, McCarrison JM, Nelson KE, Wang C, Miller CS. 13 October 2016. HSV-1 clinical isolates with unique in vivo and in vitro phenotypes and insight into genomic differences. *J Neurovirol* <https://doi.org/10.1007/s13365-016-0485-9>.
 107. Kolb AW, Adams M, Cabot EL, Craven M, Brandt CR. 2011. Multiplex sequencing of seven ocular herpes simplex virus type-1 genomes: phylogeny, sequence variability, and SNP distribution. *Invest Ophthalmol Vis Sci* 52:9061–9073. <https://doi.org/10.1167/iovs.11-7812>.
 108. Suenaga T, Kohyama M, Hirayasu K, Arase H. 2014. Engineering large viral DNA genomes using the CRISPR-Cas9 system: editing of viral genomes with CRISPR-Cas9. *Microbiol Immunol* 58:513–522. <https://doi.org/10.1111/1348-0421.12180>.
 109. Russell TA, Stefanovic T, Tschärke DC. 2015. Engineering herpes simplex viruses by infection-transfection methods including recombination site targeting by CRISPR-Cas9 nucleases. *J Virol Methods* 213:18–25. <https://doi.org/10.1016/j.jviromet.2014.11.009>.
 110. van Diemen FR, Kruse EM, Hooykaas MJG, Bruggeling CE, Schürch AC, van Ham PM, Imhof SM, Nijhuis M, Wiertz EJHJ, Lebbink RJ. 2016. CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. *PLoS Pathog* 12:e1005701. <https://doi.org/10.1371/journal.ppat.1005701>.
 111. Dutilh BE, Backus L, Edwards RA, Wels M, Bayjanov JR, van Hijum SAFT. 2013. Explaining microbial phenotypes on a genomic scale: GWAS for microbes. *Brief Funct Genomics* 12:366–380. <https://doi.org/10.1093/bfpg/elt008>.
 112. Power RA, Parkhill J, de Oliveira T. 2017. Microbial genome-wide association studies: lessons from human GWAS. *Nat Rev Genet* 18:41–50. <https://doi.org/10.1038/nrg.2016.132>.
 113. Kolb AW, Lee K, Larsen I, Craven M, Brandt CR. 2016. Quantitative trait locus based virulence determinant mapping of the HSV-1 genome in murine ocular infection: genes involved in viral regulatory and innate immune networks contribute to virulence. *PLoS Pathog* 12:e1005499. <https://doi.org/10.1371/journal.ppat.1005499>.
 114. Lee K, Kolb AW, Larsen I, Craven M, Brandt CR. 2016. Mapping murine corneal neovascularization and weight loss virulence determinants in the herpes simplex virus 1 genome and the detection of an epistatic interaction between the UL and IRS/US regions. *J Virol* 90:8115–8131. <https://doi.org/10.1128/JVI.00821-16>.
 115. Roizman B, Campadelli-Fiume G. 2007. Alphaherpes viral genes and their functions, p 70–83. *In Human Herpesviruses: Biology, Therapy, and Immunophylaxis*. Cambridge University Press, Cambridge, United Kingdom.
 116. Dunn W, Chou C, Li H, Hai R, Patterson D, Stolc V, Zhu H, Liu F. 2003. Functional profiling of a human cytomegalovirus genome. *Proc Natl Acad Sci U S A* 100:14223–14228. <https://doi.org/10.1073/pnas.2334032100>.
 117. Arav-Boger R. 2015. Strain variation and disease severity in congenital cytomegalovirus infection. *Infect Dis Clin North Am* 29:401–414. <https://doi.org/10.1016/j.idc.2015.05.009>.
 118. Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A, D'Erchia AM, Buscarinu MC, Agliardi C, Annibali V, Serafini B, Rosicarelli B, Romano S, Angelini DF, Ricigliano VA, Buttari F, Battistini L, Centonze D, Guerini FR, D'Alfonso S, Pesole G, Salvetti M, Ristori G. 2015. Epstein-Barr virus genetic variants are associated with multiple sclerosis. *Neurology* 84:1362–1368. <https://doi.org/10.1212/WNL.0000000000001420>.
 119. Zhang E, Bell AJ, Wilkie GS, Suárez NM, Batini C, Veal CD, Armendáriz-Castillo I, Neumann R, Cotton VE, Huang Y, Porteous DJ, Jarrett RF, Davison AJ, Royle NJ. 2017. Inherited chromosomally integrated human herpesvirus 6 genomes are ancient, intact, and potentially able to reactivate from telomeres. *J Virol* 91:e01137-17. <https://doi.org/10.1128/JVI.01137-17>.

Daniel W. Renner earned Bachelor of Science and Masters of Bioinformatics degrees at the Virginia Commonwealth University in Richmond, VA. As an undergraduate, Renner participated in the Science Education Alliance—Phage Hunters Advancing Genomes and Evolutionary Science (SEA-PHAGES) program and later served as a teaching assistant for both the wet laboratory and viral assembly/genomics components of the program. SEA-PHAGES, along with an internship at the Bioinformatics Core Computational Laboratory, inspired his current interest in viral comparative genomics and assembly, which continues with his ongoing research. Mr. Renner joined the Szpara laboratory at the Pennsylvania State University as a Computational Scientist in October 2014. He now leads the laboratory's computational and bioinformatics analyses with a focus on viral assembly, diversity, and genetic links to virulence. Mr. Renner also helped to produce and continues to support the Szpara laboratory's public open-source workflows for genome assembly and comparison.



Moriah L. Szpara earned a Bachelor of Science degree at the Pennsylvania State University and a PhD in Molecular and Cell Biology at the University of California, Berkeley. Dr. Szpara trained as a postdoctoral fellow with Dr. Lynn Enquist at Princeton University. Dr. Szpara now leads a laboratory as an Assistant Professor at the Pennsylvania State University in the Department of Biochemistry and Molecular Biology, Center for Infectious Disease Dynamics, and the Huck Institutes for the Life Sciences. Dr. Szpara initiated her research in viral comparative genomics in the collaborative environment of the Lewis-Sigler Institute for Integrative Genomics at Princeton University. Dr. Szpara's laboratory at Penn State is focused on dissecting viral genetic contributions to virulence, the nature of viral diversity in clinical settings, and the molecular interactions of viruses with neurons. The Szpara laboratory has also produced open-source software packages to facilitate herpesvirus genome assembly and comparison, including VirGA and VirAmp (<http://szparalab.psu.edu/>).

